Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Epoetin Alfa (EPO) Improves and Maintains Health-Related Quality of Life (HRQL) in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV): HRQL Results from the Proactive Study

Epoetin Alfa (EPO) Improves and Maintains Health-Related Quality of Life (HRQL) in Anemic HCV-Infected Patients Receiving Interferon/Ribavirin (IFN/RBV): HRQL Results from the Proactive Study. Hepatology. 2003; 38(4):302-3A.


Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.